Zacks Research Analysts Lift Earnings Estimates for Qiagen

Key Points

• Zacks Research analysts have raised their Q3 2025 earnings per share estimate for Qiagen from $0.57 to $0.59, reflecting a positive outlook for the company.
• Bank of America and UBS Group both increased their price targets for Qiagen, indicating growing confidence in its market position, with price targets now set at $53.00 and $50.00 respectively.
• The company recently reported earnings of $0.60 per share for Q2 2025, meeting consensus estimates, with a year-over-year revenue increase of 7.7%.

Qiagen N.V. (NYSE:QGEN - Free Report) - Stock analysts at Zacks Research raised their Q3 2025 earnings per share estimates for Qiagen in a research report issued to clients and investors on Tuesday, August 26th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.59 for the quarter, up from their previous estimate of $0.57. The consensus estimate for Qiagen's current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen's Q4 2025 earnings at $0.59 EPS, FY2025 earnings at $2.34 EPS, Q1 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.63 EPS, FY2026 earnings at $2.46 EPS, Q1 2027 earnings at $0.63 EPS and FY2027 earnings at $2.72 EPS.

A number of other brokerages have also commented on QGEN. Bank of America increased their price target on Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. UBS Group increased their price target on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Wall Street Zen lowered Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Cowen reissued a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Barclays initiated coverage on Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Three research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Qiagen currently has an average rating of "Hold" and a consensus price target of $49.69.

Qiagen Price Performance

Shares of Qiagen stock opened at $46.07 on Friday. The stock has a 50 day moving average of $48.71 and a 200 day moving average of $44.06. Qiagen has a 12 month low of $37.63 and a 12 month high of $51.88. The firm has a market cap of $10.24 billion, a PE ratio of 27.22, a PEG ratio of 2.52 and a beta of 0.64. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same quarter last year, the business posted $0.55 earnings per share. The firm's revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS.

Institutional Investors Weigh In On Qiagen

Institutional investors have recently modified their holdings of the stock. Amalgamated Bank lifted its stake in shares of Qiagen by 1.8% during the 2nd quarter. Amalgamated Bank now owns 11,751 shares of the company's stock worth $565,000 after acquiring an additional 209 shares during the last quarter. Atria Investments Inc increased its holdings in Qiagen by 2.9% during the 2nd quarter. Atria Investments Inc now owns 7,674 shares of the company's stock worth $369,000 after purchasing an additional 218 shares during the period. ANTIPODES PARTNERS Ltd increased its holdings in Qiagen by 9.4% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 2,566 shares of the company's stock worth $123,000 after purchasing an additional 221 shares during the period. Yousif Capital Management LLC increased its holdings in Qiagen by 3.7% during the 2nd quarter. Yousif Capital Management LLC now owns 6,257 shares of the company's stock worth $301,000 after purchasing an additional 222 shares during the period. Finally, Exchange Traded Concepts LLC increased its holdings in Qiagen by 2.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after purchasing an additional 395 shares during the period. 70.00% of the stock is owned by institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.